Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Genmab
Genmab
Activities:
Ingredients
Research & Development
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
KBI Biopharma extends contract with a big pharma giant after a successful FDA inspection
The contract has been renewed and extended until at least 2029, and will now include the purchase of two therapeutic products
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
New FAIRY viral assay could 'revolutionise' the response to future pandemics
The assay, which can detect the infectiousness of a virus in a matter of minutes, offers a quicker and cheaper alternative to the standard cell culture approach
New advice from BOLA and Labtex on cleaning and handling of PTFE products after use
The companies share: "Abrasive scouring agents may result in a milkiness of the vessels made of PFA and FEP. You may use all neutral detergents (pH 7). For higher contamination...
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Research & Development
Genmab finalises ProfoundBio acquisition
The $1.8bn acquisition allows Genmab exclusive access to ProfoundBio's clinical stage ADC Rina-S, as well as its ADC technology platforms
Regulatory
Tivdak receives US FDA approval for treating recurrent cervical cancer
The full approval of tisotumab vedotin will offer a treatment for patients with metastatic or recurrent cervical cancer exhibiting disease progression on or after chemotherapy
Drug Delivery
Partnership advances antibody therapies in immunology
Genmab and argenx have entered a multiyear collaboration, bringing together capabilities to jointly discover, develop and commercialise antibody therapies
Regulatory
ImaginAb announces supply agreement with Genmab
The non-exclusive worldwide agreement provides Genmab a license to use the company’s CD8 ImmunoPET imaging technology
Research & Development
Genmab and Synaffix enter into ADC license agreement
Genmab will be responsible for the research, development, manufacturing and commercialisation of any resulting ADC therapies
Manufacturing
Genmab chooses Ibex to take gene candidates to IND in 12 months
New contract extends the partnership between the Danish biotech company and Lonza
Research & Development
Personalised cancer treatment 2.0: new combination strategy developed
Tumours often comprise groups of cancer cells that show differential drug sensitivities, one of the reasons that initially effective treatments usually do not lead to long-term benefit in patients
Subscribe now